


Listing of Claims:

Please cancel claims 1-48 and add new claims 49-88 as follows:

1-48. (Canceled)

49. (New) A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of 20(S)-1 α ,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃ having the structure



50. (New) The method of claim 49 where the disease is leukemia.

51. (New) The method of claim 49 where the disease is colon cancer.

52. (New) The method of claim 49 where the disease is breast cancer.

53. (New) The method of claim 49 where the disease is prostate cancer.

54. (New) The method of claim 49 wherein the compound is administered orally.


55. (New) The method of claim 49 wherein the compound is administered parenterally.

56. (New) The method of claim 49 wherein the compound is administered transdermally.

57. (New) The method of claim 49 wherein said effective amount comprises about 0.01 μ g/day to about 100 μ g/day of 20(S)-1 α ,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃.

58. (New) The method of claim 49 wherein said effective amount comprises about 0.1 μ g/day to about 50 μ g/day of 20(S)-1 α ,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃.

59. (New) A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃ having the structure



60. (New) The method of claim 59 where the disease is leukemia.

61. (New) The method of claim 59 where the disease is colon cancer.

62. (New) The method of claim 59 where the disease is breast cancer.

63. (New) The method of claim 59 where the disease is prostate cancer.

64. (New) The method of claim 59 wherein the compound is administered orally.


65. (New) The method of claim 59 wherein the compound is administered parenterally.

66. (New) The method of claim 59 wherein the compound is administered transdermally.

67. (New) The method of claim 59 wherein said effective amount comprises about 0.01µg/day to about 100µg/day of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃.

68. (New) The method of claim 59 wherein said effective amount comprises about 0.1 µg/day to about 50 µg/day of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃.

69. (New) A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of 20(S)-1 α ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃ having the structure



70. (New) The method of claim 69 where the disease is leukemia.

71. (New) The method of claim 69 where the disease is colon cancer.

72. (New) The method of claim 69 where the disease is breast cancer.

73. (New) The method of claim 69 where the disease is prostate cancer.

74. (New) The method of claim 69 wherein the compound is administered orally.


75. (New) The method of claim 69 wherein the compound is administered parenterally.

76. (New) The method of claim 69 wherein the compound is administered transdermally.

77. (New) The method of claim 69 wherein said effective amount comprises about 0.01 $\mu\text{g/day}$ to about 100 $\mu\text{g/day}$ of 20(S)-1 α ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃.

78. (New) The method of claim 69 wherein said effective amount comprises about 0.1 $\mu\text{g/day}$ to about 50 $\mu\text{g/day}$ of 20(S)-1 α ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃.

79. (New) A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-1 α -hydroxy-2-methylene-24-dehydro-19-norvitamin D₃ having the structure



80. (New) The method of claim 79 where the disease is leukemia.
81. (New) The method of claim 79 where the disease is colon cancer.
82. (New) The method of claim 79 where the disease is breast cancer.
83. (New) The method of claim 79 where the disease is prostate cancer.
84. (New) The method of claim 79 wherein the compound is administered orally.
85. (New) The method of claim 79 wherein the compound is administered parenterally.
86. (New) The method of claim 79 wherein the compound is administered transdermally.
87. (New) The method of claim 79 wherein said effective amount comprises about 0.01 µg/day to about 100 µg/day of 20(S)-26,27-dimethylene-1α-hydroxy-2-methylene-24-dehydro-19-norvitamin D₃.
88. (New) The method of claim 79 wherein said effective amount comprises about 0.1 µg/day to about 50 µg/day of 20(S)-26,27-dimethyl-1α-hydroxy-2-methylene-24-dehydro-19-norvitamin D₃.